Vol 8-1 Mini Review

Gaps in Microbial Risk Management Guidance for Users of Expressed Breastmilk

Devin Daeschel1, Maria Amalia Beary1, Sarah M Reyes2, Abigail B. Snyder1

1Department of Food Science and Technology, Cornell University, Ithaca, NY, USA

2Rev Bioscience, LLC, Boise, ID, USA

Expressed breastmilk (EBM) is used in various use-contexts ranging from home feeding of healthy full term, older infants to neonatal intensive care units (NICUs) administering pasteurized donor EBM to medically fragile premature newborns. In some cases, contaminated EBM has been the source of microbial pathogens that caused infection in vulnerable infants. However, microbial risk management guidance has evolved unevenly across different EBM use-contexts. Recommendations are not often stratified by risk, may be difficult for working parents to implement, or limited in some use-contexts such as peer-to-peer EBM sharing and commercial fee-for-service processing. This review characterizes the various EBM use-contexts and the microbial risk management strategies (e.g., process controls, preventative hygiene and sanitation, microbiological criteria) used to reduce the risk of EBM-mediated infections in infants. We examine microbial safety guidance developed by various organizations and identify gaps in risk stratification, regulatory oversight, and feasibility. In some cases, current guidance is poorly targeted to the infants at greatest risk. While in lower-risk contexts, exacting or inconsistent recommendations can increase caregiver burden without clear clinical benefit. Risk managers and risk communicators should align guidance with infant vulnerability. Guidance on strategies applicable to high-risk settings such as NICUs should be prioritized and the burden in low-risk, parent-managed settings that does not reduce risk should be considered.

DOI: 10.29245/2689-9981/2026/1.1189 View / Download Pdf
Vol 8-1 Commentary and Opinion Article

Commentary: Transient Elastography and Fibrosis-4 Index as Predictors of Hepatocellular Carcinoma in Hepatitis C Virus Patients with Sustained Virological Response

1,2Paula G F da Silva, 3Flávia F Fernandes,1Cristiane A Villela-Nogueira

1Clementino Fraga Filho University Hospital, School of Medicine, Hepatology Division, Federal University of Rio de Janeiro, Brazil.

2Bonsucesso Federal Hospital, Department of Hepatology, Rio de Janeiro, Brazil.

3Pedro Ernesto University Hospital, Internal Medicine Department and Obesity Unit (SAI-Ob) Multiuse Clinical Research Center (CePeM), Rio de Janeiro, Brazil.

Global data from 2020 estimates that 57 million people have chronic hepatitis C virus (HCV) infection, accounting for 300,000 disease-related deaths and 1.5 million new infections annually1. In Brazil, from 2000 to 2024, 342,328 confirmed cases of infection were recorded, most of which were chronic2.

Follow-up of patients with HCV-related liver disease has advanced considerably over the past two decades3. Studies culminated in the development of direct-acting antiviral (DAA) therapy with high efficacy in achieving sustained virological response (SVR) for both acute and chronic infections1, 4. HCV eradication rates average 90-97%5.

DOI: 10.29245/2689-9981/2026/1.1190 View / Download Pdf